Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2–ERK 1/2 pathway
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0292628 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Koki Maeda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Liver, MAP Kinase Signaling System, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI.
Abstract (Originalsprache)
Hepatic ischemia-reperfusion injury causes liver damage during surgery. In hepatic ischemia-reperfusion injury, the blood coagulation cascade is activated, causing microcirculatory incompetence and cellular injury. Coagulation factor Xa (FXa)- protease-activated receptor (PAR)-2 signaling activates inflammatory reactions and the cytoprotective effect of FXa inhibitor in several organs. However, no studies have elucidated the significance of FXa inhibition on hepatic ischemia-reperfusion injury. The present study elucidated the treatment effect of an FXa inhibitor, edoxaban, on hepatic ischemia-reperfusion injury, focusing on FXa-PAR-2 signaling. A 60 min hepatic partial-warm ischemia-reperfusion injury mouse model and a hypoxia-reoxygenation model of hepatic sinusoidal endothelial cells were used. Ischemia-reperfusion injury mice and hepatic sinusoidal endothelial cells were treated and pretreated, respectively with or without edoxaban. They were incubated during hypoxia/reoxygenation in vitro . Cell signaling was evaluated using the PAR-2 knockdown model. In ischemia-reperfusion injury mice, edoxaban treatment significantly attenuated fibrin deposition in the sinusoids and liver histological damage and resulted in both anti-inflammatory and antiapoptotic effects. Hepatic ischemia-reperfusion injury upregulated PAR-2 generation and enhanced extracellular signal-regulated kinase 1/2 (ERK 1/2) activation; however, edoxaban treatment reduced PAR-2 generation and suppressed ERK 1/2 activation in vivo . In the hypoxia/reoxygenation model of sinusoidal endothelial cells, hypoxia/reoxygenation stress increased FXa generation and induced cytotoxic effects. Edoxaban protected sinusoidal endothelial cells from hypoxia/reoxygenation stress and reduced ERK 1/2 activation. PAR-2 knockdown in the sinusoidal endothelial cells ameliorated hypoxia/reoxygenation stress-induced cytotoxicity and suppressed ERK 1/2 phosphorylation. Thus, edoxaban ameliorated hepatic ischemia-reperfusion injury in mice by protecting against micro-thrombosis in sinusoids and suppressing FXa-PAR-2-induced inflammation in the sinusoidal endothelial cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
ORCID-Profile: Koki Maeda, Naohisa Kuriyama
Förderung
- Japan Society for the Promotion of Science KAKENHI
Zitieren
APA
Maeda, K., Kuriyama, N., Noguchi, D., Ito, T., Gyoten, K., Hayasaki, A., Fujii, T., Iizawa, Y., Murata, Y., Tanemura, A., Kishiwada, M., & Mizuno, S. (2024). Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2–ERK 1/2 pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0292628
Vancouver
Maeda K, Kuriyama N, Noguchi D, Ito T, Gyoten K, Hayasaki A, et al. Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2–ERK 1/2 pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0292628
BibTeX
@article{Maeda2024,
author = {Maeda, Koki and Kuriyama, Naohisa and Noguchi, Daisuke and Ito, Takahiro and Gyoten, Kazuyuki and Hayasaki, Aoi and Fujii, Takehiro and Iizawa, Yusuke and Murata, Yasuhiro and Tanemura, Akihiro and Kishiwada, Masashi and Mizuno, Shugo},
title = {Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2–ERK 1/2 pathway},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0292628}
}
EUVIMED